I know they paid .20 but on the day of purchase the price was .15 and it
has yet to go above .20 since 2/15. I give the Dicke's a world of credit
for following through to buy at .20 when the price was below that.
That's why I question whether it's their shares selling now to finance
the Dicke's are selling don't they have to file with the SEC? (I think
they own more than 4% of the outstanding shares)
will open the advr book to chapter 2,888,000 printed in 1986 the last
chapter in ??????
wanted to see what its like to post a zillion times in a row about
nothing like the people i have on ignore everybody have a good weekend
right Zenna! The .103 was so depressing I guess I blocked it out of my
mind temporarily. You presented a more accurate picture. Also new
investors watch these intra-day charts closely.
I've been following your posts here and you seem to know what you're talking about which is a real welcomed "plus" for this forum. Sure beats all this personal back-stabbing stuff that goes on. We need more voices like yours and less of some others.
Have a great weekend!
On February 3, 2004, Advanced Viral entered into an agreement with James Dicke II and his son James Dicke III, whereby Advanced Viral agreed to sell an aggregate of 120,000,000 shares of its Common Stock and warrants to purchase 15,000,000 shares of its Common Stock for an aggregate purchase price of $12,000,000......
(Note: 120,000,000 for $12,000,000 = .10 per share.)
......Pursuant to the Securities Purchase Agreement, a copy of which is included in the Current Report on Form 8-K dated February 3, 2004 as Exhibit 10.1, the funding shall take place in four equal stages of $3,000,000 each, once every 90 days with the first $3,000,000 funding to occur February 5, 2004. In addition, Advanced Viral granted demand and piggback registration rights to the investors for the shares issued or issuable in connection with the transaction pursuant to the terms of the Registration Rights Agreement, a copy of which is included in the Current Report on Form 8-K as Exhibit 10.2. James F. Dicke II is the Chairman and CEO of Crown Equipment Corporation and a former member of the Board of Directors of Advanced Viral.
The deal calls for the delivery by ADVR of 30,000,000 every three months, in consideration of the Dicke's $3,000,000 every three months.....Give the Dicke's all the credit you want, but you should at least understand the terms of the deal that you are "giving them credit" for......
Hope this helps.....I feel much better now.....
Sorry, the highlighted line got left out of my last post.....
On February 3, 2004, Advanced Viral entered into an agreement with James Dicke II and his son James Dicke III, whereby Advanced Viral agreed to sell an aggregate of 120,000,000 shares of its Common Stock and warrants to purchase 15,000,000 shares of its Common Stock for an aggregate purchase price of $12,000,000. Pursuant to the Securities Purchase Agreement, a copy of which is included in the Current Report on Form 8-K dated February 3, 2004 as Exhibit 10.1, the funding shall take place in four equal stages of $3,000,000 each, once every 90 days with the first $3,000,000 funding to occur February 5, 2004. The warrants have an exercise price of $0.20 per share and are exercisable at any time through February 2, 2007. In addition, Advanced Viral granted demand and piggback registration rights to the investors for the shares issued or issuable in connection with the transaction pursuant to the terms of the Registration Rights Agreement, a copy of which is included in the Current Report on Form 8-K as Exhibit 10.2. James F. Dicke II is the Chairman and CEO of Crown Equipment Corporation and a former member of the Board of Directors of Advanced Viral.
If ADVR had ANYTHING to do with the pumping newsletter (contacts, phone calls, or/and emails) that was sent to millions of potential penny investors Friday (and really not mentioning ANYTHING we don't already know or isn't posted on ADVR's Web page), are they legally culpable in terms of aiding and abetting the manipulation of prices by behind-the-scenes-communications using a spamming newsletter??
And add to that, did any cash change hands from ADVR and the newsletter/email? Did the newsletter owners or employees buy shares in anticipation of the spam so that they lined their own pockets??
A long time ago, ADVR was involved in a case that is similar to this.
Curious minds are interested.
If in fact the ENTIRE debacle is based on a simple newsletter publicizing the ADVR and no news at all, is this a fair way for traders who know this is going out beforehand?
Is there any tie-in with the Dicke financing?
If the news is JUST the pumping newsletter, all traders better watch their back when the end-point is reached the drop will be precipitous and the shares traded will be huge!!
Good luck all!!
what do you do for a living? Work for the CIA and sit around and think
up conspiracy theories? Digging kind of deep aren't ya? However, I
wouldn't be surprised if advr was behind the newsletter in some way. The
pps could drop some the first couple of days next week, but I still
believe this stock has big run left in her before the end of June. 23
million + shares could be the beginning. Don't know for sure, but still
like the action.
was thinking the share price would rise more with the amount of action
on Friday, but I'm really just glad it wasn't a one day pump and dump,
and didn't end up below where it started the day. IMO there's a
substantial amount of traders out there who haven't even seen the
newsletter yet, plus the patient money who just sat on the sidelines
Friday waiting to see what happened at the end of the day. Probably be
an early drop next week, but I'm guessing advr will shoot quite a bit
higher. This may not be the big run I'm expecting, but it could still be
a good runup. Not positive, but hoping.
- - - - -
has it that Mr. Dicke has no plans to sell anything. Everything can
change. The new CEO will need to prove success. Are there any posters
here who are in on the letter?
- - - - -
do you do for a living? Work for the CIA and sit around and think up
Unbeknownest to you, my buddy, is the fact that ADVR was mentioned in a newsletter scam (convictions obtained by the SEC from the perps of the newsletter - who pumped stocks via this method) in which a similar thing happened.
Before you go tooting your horn about what _I_ do or how _I_ think, go back in ADVR history and do some homework. Though ADVR was not indicted, there were connections of some sort.
Don't ask ME about this event, ASK the pumpers who publish the newsletter. It's not about JUST the cash you made, it's about HOW this cash is generated - and exactly what is wrong with America...so long as you got the dollar, don't worry about HOW you got it.
PUMP newsletter has been posted several times on this board......Will
someone please post the entire newsletter?????
I.E. The disclaimer at the bottom of the page in compliance with Section 17(b), that tells how much the promoter is being paid & by whom......
yanks- Rumor also has it that a bird in the hand is better than two in
Whatever the rumor is......Does it really make sense to anyone that large shareholders with no reporting requirements, that hold totally unrestricted shares, would pass up an opportunity to make at least $4,500,000 on a $3,000,000 every three months ?????
Neither of us has any way of knowing with any certainty, if the Dicke's are short term or long term stockholders. What we do know is this, the contract between ADVR & the Dicke's specifically calls for the shares that they buy to be "unrestricted". This clearly means that they can sell at will. If, in fact the contract called for them to hold the shares for a predetermined period of time, then we could be sure that they are in fact holding....but, it doesn't, so we can't......
IMO- The contract is fully designed for the Dicke's to utilize the option of pulling profit every three months prior to the next round of $3,000,000 investment. Ask yourself, "Why didn't they just pony up the 12 million all at once ?".......I say, that if they were truly interested in the long term success of the company & drug, they would have done just that......
Cancer Still Cutting Many Lives Short"
Reuters Health (04.22.04)::Amy Norton
Unlike in wealthy nations where cervical cancer deaths have
plunged in the past 50 years, the disease remains a top killer of younger women in many parts of the world, according to new research. Study author Dr. Zuo-Feng Zhang of the University of California-Los Angeles said the findings demonstrate the need for more prevention and screening in developing nations.
Zhang and colleagues used the "years of life lost" measure
to examine the impact of cervical cancer among women ages 25 to 64 in 2000. Unlike a simple death rate, this measure takes into account a woman's age at death versus her life expectancy. In the global analysis, AIDS was responsible for the most years lost by far, followed by complications due to pregnancy and childbirth, and tuberculosis.
In Latin America and the Caribbean, however, cervical cancer resulted in the most years lost. In sub-Saharan Africa and south-central Asia, women lost more years of life to cervical cancer than any other cancer. In most other world regions, breast cancer resulted in the most years lost.
Cervical cancer is most often caused by infection with
certain strains of the sexually transmitted human papillomavirus (HPV). Women can lower their risk of HPV and cervical cancer by not having sex before age 18 and by limiting their number of sexual partners. In the developed world, routine Pap testing - which can detect early cancer as well as precancerous cells - is credited for the drop in cervical cancer deaths. But in poor countries, routine Pap tests are not feasible and education on cervical cancer risk factors is lacking. As a result, more than 80 percent of cervical cancer cases globally occur in these
Poor countries, Zhang said, need help from wealthier ones
and from international aid agencies to educate women about
cervical cancer and to improve screening. While he acknowledged that many poor countries lack the laboratory resources to conduct and interpret Pap tests, he said one alternative is a simple visual inspection of the cervix.
Though not as sensitive as the Pap test, "it's better than nothing," Zhang said.
The full report, "Cervical Cancer as a Priority for
Prevention in Different World Regions: An Evaluation Using Years of Life Lost," was published in the International Journal of Cancer (2004;109(3):418-424).
Advanced Viral Research Corporation Waits for Results of AVR118's Cacehxia Trial
By Chael Needle
Advanced Viral Research Corporation (ADVR) has released a forward-looking preliminary sketch of forthcoming results of a clinical trial in Israel studying the safety of AVR118 (formerly called Product R), an immunomodulator, in its treatment of body wasting. The results have not been published yet and cannot be reviewed, but ADVR decided to send out a press release claiming that the first fifteen patients in the study, all of whom were experiencing body wasting as well as failing HAART regimens, showed improvement in appetite, weight gain or stability, and enhanced quality of life; none reported significant side effects. Readers should note the smallness of the sample—not because it’s unusual for a Phase I trial, but because it’s too early to tell if these results can be replicated and if the other fifteen patients that will complete the results will make good on the theorized safety and efficacy. The only FDA-approved treatment for body wasting in individuals with HIV/AIDS so far is the recombinant human growth hormone, somatropin.
I had interviewed Dr. Shalom Z. Hirschman, then-President and CEO of ADVR, in November 2002 for this column. At the time, Dr. Hirschman was excited about the Israeli studies, which would look at the immunomodulator as a possible salvage therapy for patients failing HAART, as well as a treatment that could reverse body wasting and mitigate the toxicities of HAART drugs. I was expecting to hear results about AVR118 as a salvage-therapy candidate. As it turns out, the only results offered so far concern body wasting. An important quality-of-life issue, to be sure, but the absence of news about other trial goals is disappointing.
“When we looked the raw data that was published—or, rather, put out into the press release—what we found was that virtually every patient had a response. In other words, all patients had a response, “ says Dr. James D’Olimpio, M.D., Director of the North Shore University Hospital’s Supportive Oncology and Palliative Care Service in Manhasset New York, and a member of ADVR’s Scientific Advisory Board as well the company’s spokesperson. “All fifteen patients responded in the kind of parameters [one needs] to publish with. I can’t get into that right now because the database isn’t complete.” Though he is not participating as a researcher in the trial, he has treated body wasting in patients with cancer as well as those with HIV/AIDS since the mid-eighties and has researched body wasting for the past five years. He sees this trial as part of new scientific attention being devoted to understanding body wasting. Any drug that is eventually developed, however, won’t be a “magic bullet, or monotherapy. It’s going to be a number of things. We’re building pieces of the puzzle,” he says. “AVR118 could be something we can use to reverse the process of body wasting.”
Dr. D’Olimpio has found that treating body wasting, or cachexia, in patients with cancer dovetails with patients with HIV disease. Body wasting is caused by different things in each but they do have similar models in the sense that “both have a number of different inflammatory pathways that become activated” in common. Says Dr. D’Olimpio: “The key feature in both situations is that skeletal muscle, what’s called lean body mass, is significantly affected. Once skeletal muscle is affected, then the body cannot fight it off from the standpoint of immune response or from the standpoint of being able to tolerate therapy.” The organs cannot support themselves as a result and eventually deteriorate, he says, as evidenced by the “20,000 individuals who ultimately die of HIV disease each year who lose weight as the key feature of why they get infections or why infections lead to weight loss.” He continues: “The weight loss itself is a reflection of this inflammatory process by which patients cannot muster an effective response and/or tolerate their treatments.”
One present goal for treatment research in general is to find drugs that down-regulate or interrupt these pathways. The targets are the signals that tell the body to siphon off protein from muscle and, in effect, keep aberrant inflammatory processes going. EPA, a fatty acid, and amino acids have been found to dampen signals, according to D’Olimpio. “It also seems that AVR118 does this. The information coming out is worthy of scientific publication.” At this point, however, all we can do is wait and see if a new treatment for body wasting is indeed on the way.
Chael Needle reported on cardiovascular disease and HIV for the December 2003 issue.
n/a P/E Ratio:
n/a 52 Week Range:
0.012 to 0.30
After Hours Trading
4/23/2004 4:03:00 PM Last:
or click here for the email version with charts
I must admit I am embarrassed about trying to make a point without the right info. I don't know how but I read the PR and 8K when they first came out and I got it wrong from the start. I don't talk about this stock with anybody who knows it so I never got the correction until now.....thanks.
I do feel the Dicke's are already rich so they are not trading now to pay for May's transaction. They are not in it to make a profit. They are in it to be super rich. (120,000,000 shares by 1.00 = alot)
hear the MM scumbags tried to list ADVR overseas..
on British and German exchanges WITHOUT the company's permission? Probably another method of MM's attempting to short it. What scumbags.. and what is worse, what scumbags are the SEC and NASD for permitting these thieves to screw us as they do..